Systematic review

Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials

Jimmy Wen, Burhaan Syed, Solomon Kim, Mouhamad Shehabat, Ubaid Ansari, Daniel I Razick, Muzammil Akhtar, David Pai

Cureus · 2024 · 16(8):e65961

Original publication PubMed Full text on PMC

Study at a glance

Design: PRISMA-guided systematic review of randomized controlled trials
Population or model: Adults in randomized NMN supplementation trials
Sample size: 10 studies; 437 participants
Intervention: NMN 150–1,200 mg/day; mean follow-up 9.6 weeks
Publication type: Systematic review
Evidence class: review-perspective
Research area: Physical performance and safety
Trial registration: Not applicable.

Study endpoints

Grip strength
Skeletal mass index
Other physical-performance measures
Adverse events

Plain-language summary

This systematic review examined ten randomized NMN studies involving 437 participants and focused on physical performance and safety.

Average grip strength and skeletal-mass-index values changed only modestly, and the review described physical-performance improvements as non-significant overall.

No serious adverse effects were identified in the included trials, but the available trials were short and heterogeneous.

Key findings

Ten randomized studies and 437 participants were included.
NMN doses ranged from 150 to 1,200 mg/day.
Physical-performance parameters showed non-significant improvement overall.
No serious adverse effects were observed in the included trials.

Limitations

The included trials used different performance tests, doses and populations.
Many individual performance outcomes were available from only a few studies.
Follow-up was short, averaging under 10 weeks.
Absence of serious adverse events in small short trials does not establish long-term safety.

Funding and transparency

Funding

The authors declared that no financial support was received for the submitted work.

Competing interests

The authors declared no relevant financial or non-financial relationships.

HealthspanX observation

The review does not support converting isolated positive performance endpoints from individual trials into a broad physical-performance claim.

Interpretive weight

Limited

Systematic review of ten RCTs, but physical-performance measures were incompletely and heterogeneously reported and improvements were not statistically significant overall.

This record summarizes a publication; it is not medical advice or a claim that a HealthspanX product reproduces the study's results. Report a correction.

Explore HealthspanX

Science

Your wellbeing